3-(2-(TRIMETHYLSILYL)ETHOXYMETHOXY)-PYRIDINE | 130332-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-(TRIMETHYLSILYL)ETHOXYMETHOXY)-PYRIDINE
• 英文别名: 3-{[2-(trimethylsilyl)ethyl]oxymethyloxy}pyridine；3-(2-Trimethylsilylethoxymethoxy)-pyridine；trimethyl-[2-(pyridin-3-yloxymethoxy)ethyl]silane
• CAS: 130332-94-4
• 化学式: C₁₁H₁₉NO₂Si
• 分子量: 225.363
• InChiKey: DNRFJJMFYWJGIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-(TRIMETHYLSILYL)ETHOXYMETHOXY)-PYRIDINE 在 叔丁基锂 、 戴斯-马丁氧化剂 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 正戊烷 为溶剂， 反应 10.17h， 生成 (4-cyclopropylphenyl)-(3-hydroxypyridin-4-yl)methanone
  参考文献：
  名称：

  EP1783110

  摘要：

  公开号：
• 作为产物：
  描述：

  3-羟基吡啶 在 sodium hydride 作用下， 以 乙二醇二甲醚 为溶剂， 反应 15.33h， 生成 3-(2-(TRIMETHYLSILYL)ETHOXYMETHOXY)-PYRIDINE
  参考文献：
  名称：

  EP1783110

  摘要：

  公开号：

文献信息

• The 2-(trimethylsilyl)ethoxymethoxy (OSEM) directed ortho metalation group. New regiospecific synthetic routes to substituted benzenes and pyridines
  作者：Saumitra Sengupta、Victor Snieckus

  DOI：10.1016/s0040-4039(00)97597-x

  日期：——

  Regiospecific metalation of OSEM aryl (2) and 3-pyridyl (5) systems allows the preparation of diversely substituted aromatic (3, Table), 4-pyridyl (6), and, significantly, 2-pyridyl (7,9) derivatives.

  OSEM芳基（2）和3-吡啶基（5）系统的区域特异性金属化可以制备不同取代的芳族化合物（3，表），4-吡啶基（6）以及明显的2-吡啶基（7,9）衍生物。
• Triazole derivatives as tachykinin receptor antagonists
  申请人：Amegadzie Kudzovi Albert

  公开号：US20050239786A1

  公开（公告）日：2005-10-27

  This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C 1 -C 3 alkane-diyl; R 1 is phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R 4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)

  本申请涉及化合物I式或其药学上可接受的盐，其药物组合物以及其作为tachykinin受体NK-1亚型的抑制剂的用途，以及其制备过程和中间体。其中：D是C1-C3烷基二亚基；R1是苯基，可选地取代为一个至三个取代基，独立地选自卤素，C1-C4烷基，C1-C4烷氧基，氰基，二氟甲基，三氟甲基和三氟甲氧基的群；R4是从群 consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)中选择的基团。
• Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same
  申请人：Kakinuma Hiroyuki

  公开号：US20060194809A1

  公开（公告）日：2006-08-31

  There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

  提供了下列公式的杂环基5-硫基-β-D-葡萄糖苷化合物，该化合物对SGLT2活性具有抑制作用，或其药学上可接受的盐或水合物。还提供了一种制药制剂，特别是预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的药物，该制剂包含该化合物作为活性成分。
• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US07439232B2

  公开（公告）日：2008-10-21

  There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

  提供了一种杂环基5-硫基-β-D-葡萄糖苷化合物的公式，该化合物对SGLT2活性具有抑制作用，或其药学上可接受的盐或水合物。还提供了一种制药制剂，特别是用作糖尿病、糖尿病相关疾病或糖尿病并发症的预防或治疗剂，其中包含该化合物作为活性成分。